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involvement of health technology assessment institutions, the
adjustment of the reimbursement system in a time frame allow-
ing the survival of the company, and the dissemination of the
technology. RESULTS: Involvement of objective institutions like
the Federal Committee (GemBA) or the Institute for Reimburse-
ment in the hospital sector (INEK) is necessary to prevent imple-
mentation of new technologies without adequate medical
efﬁcacy and economic effectiveness. For positive recommenda-
tions a critical mass of clinical and health economic studies is
prerequisite. But in time adjustment of the reimbursement cata-
logue, e.g. as new DRG or additional payment to existing DRGs,
seem to be crucial for implementation of a new costly technol-
ogy. CONCLUSION: Slow decisions processes can delay if not
prevent the use of useful new therapeutic technologies. Although
according to the German law cost effectiveness should be con-
sidered in reimbursement decisions, so far it did not play a rel-
evant role in reimbursement decisions in the hospital sector.
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OBJECTIVES: Recognizing the prescribing pattern and associ-
ated costs of psychotropic medications and the factors associated
with such prescribing is crucial and may play an important role
in improving the health care services provided to patients on such
medications. The objective of this study was to assess current
trends and factors inﬂuencing the prescribing of psychotropic
medications. The study also estimated the direct cost associated
with these medications. METHODS: This is a retrospective
study of (N = 71,136) prescription events of psychotropic med-
ications identiﬁed from outpatient pharmacy records of a major
health care system in Riyadh, Saudi Arabia for years 2002, 2003,
and 2004. Patient characteristics, psychotropic medications use
and the associated costs over the three years period were deter-
mined. Logistic regression was used to evaluate the inﬂuence of
physician specialty and other relevant factors on prescribing of
different psychotropic medications. RESULTS: Over the three
years period the use of high cost agents have sharply increased
to account for around 8% of the total outpatient spending on
pharmaceuticals in 2004. Prescriptions by General Practitioners
(GPs) accounted for 35% of the total psychotropic medications
prescribed. However, patients on these medications were more
likely to receive a high cost drug from a psychiatrist than from
any other specialty. CONCLUSIONS: The results of the study
indicate that psychotropic medications are mainly prescribed by
GPs and that the likelihood of being prescribed a psychotropic
medication, which may be of high cost, is greater when patients
see a psychiatrist. In Saudi Arabia, health care systems should
closely monitor prescribing patterns for psychotropic medica-
tions to avoid unnecessary cost and consequently, the potential
for inappropriate use of such agents.
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OBJECTIVE: To estimate the ﬁnancial effect of racial disparities
as reﬂected in differences in hospital admission rates each of the
25 Major Diagnostic Categories (MDCs) in the state of South
Carolina. METHODS: Estimates were calculated for total sub-
mitted charges within each MDC that were attributed to higher
admission rates for African Americans than for Caucasians in
South Carolina, based on age-adjusted annual admission rates.
Each of the 25 MDCs was evaluated to reveal which component
Diagnostic Related Groups (DRGs) were the largest admission
“drivers” or contributors to the observed differences in ad-
mission rates. South Carolina hospital discharge data for
1998–2002 was used for the analysis. The database includes all-
payer billing data for inpatient hospital admissions as received
on the UB-92 billing ﬁle for the covered episode. Charges were
inﬂation-adjusted to 2002 constant dollars. RESULTS: Between
1998 and 2002, there were an estimated $1.6 billion in total
charges for hospital admissions in South Carolina that were
attributed to higher age-adjusted admission rates for African-
American patients. In addition, African Americans had consis-
tently higher hospital admission rates for disease categories that
are often associated with a failure to obtain ambulatory and 
preventive care. CONCLUSION: Our analysis reveals that age-
adjusted hospital admission rates for African Americans in South
Carolina are higher than for Caucasians, and that the gap
appears to be widening over time. Given the magnitude of the
ﬁnancial implication, interventions with even a small impact on
the conditions underlying the racial disparities in hospital admis-
sions are likely to be cost-effective.
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OBJECTIVE: Health districts have been established as part of
the decentralization of responsibility within the Italian National
Health Service. A major challenge is to assure that appropriate
ﬁnancing is provided to meet the needs of the population. Risk
adjustment models are being developed that can be used for dis-
tricts’ resource allocation, planning and evaluation activities.
METHODS: Pharmaceutical, hospital, and demographic data
from 2000 and 2001 have been assembled for the entire popu-
lation of Emilia Romagna, a large northern Italian region (4
million). Pharmaceutical and hospital tariffs were a proxy for
costs. Morbidity indicators based upon pharmacy and hospital
data were developed for risk adjustment. Prospective risk adjust-
ment models were ﬁt. We tested several models of increasing
complexity, taking advantage of the predictive power of phar-
macy- and hospital-based diagnostic groups. Our ﬁnal adjuster
was based upon a combination of the pharmacy and hospital
groupings. We considered fairness across administrative units, as
equity was a key policy goal. RESULTS: The pharmacy cost
model predicts 25.8% of the variation in pharmacy costs. Our
hospital cost model predicts 10.1% of variation in prospective
hospital costs. Predictive accuracy for pharmacy cost models
were improved by information from the hospital data; and were
more stable for those who used health services in year 1, and
better for those who used hospital and pharmacy services com-
pared to those who did not have any service use. For the phar-
macy model predictive accuracy by district ranged from 0.91 to
1.10; for the hospital cost model, predictive accuracy by district
ranged from 0.93 to 1.13. CONCLUSIONS: We demonstrate
that risk adjustment models using pharmacy data to identify
individual morbidity are good predictors of future year costs.
Regional and district health managers can use these models for
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planning speciﬁc interventions and for evaluating patterns of
pharmaceutical and hospital use.
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OBJECTIVES: In Ukraine forms insurance medicine and for-
mulary system. Annually state selects more than 3% from a gross
national product. The limited tool on pharmaceuticals is insuf-
ﬁciently. METHODS: We in the commission of Health Ministry
of Ukraine have developed regulations about the National list of
the essential medicines with use the pharmacoeconomic analysis
for carrying out of the state purchases. The analysis “cost-
minimization” dominates, the analysis “cost-effectiveness” will
carry out seldom in connection with complexity of searching of
the data about effectiveness of drugs. We have developed tech-
niques the pharmacoeconomic analysis for creation of the 
formulary. RESULTS: We have created «The Program of phar-
macoeconomical evaluation of drugs in Ukraine», which
includes the education of the pharmacists on pharmacoeconom-
ics and organization of pharmacoeconomical researches. We
have developed recommendations on the pharmacoeconomic
analysis for carrying out in Ukraine in view of its economic,
demographic features. At the present stage in Ukraine the State
formulary of medicines is developed. The government is hesitant
to apply pharmacoeconomics widely in pricing and reimburse-
ment. There is a system of gathering of pharmacoepidemiologi-
cal data. Little experience exists in quality of life, measurement
and cost-utility techniques. On the basis of materials of ISPOR
we prepare the textbook “Pharmacoeconomics” by Ukrainian.
More than 4000 practical pharmacists are acquainted with phar-
macoeconomical analysis. The original educational program on
pharmacoeconomics for the clinical pharmacists is created.
CONCLUSIONS: The pharmacoeconomics is necessary for cre-
ation of the insurance medicine and State Formulary in Ukraine.
The education of the doctors and pharmacists on pharmacoeco-
nomics is necessary for improving quality spent researches. Cre-
ation of the state formulary of medicines after results the
pharmacoeconomical analysis will allow to improve medicinal
provision of the population of Ukraine.
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OBJECTIVES: To evaluate the effects of Medical Savings
Accounts (MSAs), a health care ﬁnancing method, on the health
care utilization and health expenditure of the insured employees
in China. METHODS: The study used a before and after design.
A multivariate econometric model was used to analyse the effects
of MSAs reform on the changes in health care utilization and
health expenditure, while controlling the effects of all other con-
founding factors. The use of health care and health expenditure
was modeled in a two-step process: whether or not to seek health
care; and how much to use health care and the resulting expen-
diture, giving that health care was to be used. The data are from
a series of annual surveys at the individual level conducted in a
Chinese city during 1993 to 1999. RESULTS: The use of MSAs
in the Chinese city is associated with the shift of health care 
utilization from inpatient and emergency settings to outpatient
settings. It is also associated with reduced use of high-tech diag-
nostic services. But overall health care utilization level and health
expenditure continued to increase after the MSAs reform. CON-
CLUSIONS: The use of MSAs in the Chinese city resulted in the
reduction of inpatient care and emergency care but failed to
reduce the overall health care utilization and health expenditure
per insured patient. The results suggest that MSAs may have
more income effects than substitution effects on health care 
utilization and expenditure.
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OBJECTIVES: To highlight the importance of considering both
age and gender of users (population (pop) with any prescription)
if analyzing pharmaceutical expenditure. METHODS: All
primary health care prescriptions (2003) have been considered
(95 million prescriptions; 4.2 million users; 1237 million €). Indi-
cators analyzed: prescriptions per user (P/U), cost per prescrip-
tion (C/P) and cost per user (C/U), all from administration
viewpoint. Risk of consuming (U/Pop) has been also calculated
according to age and gender. RESULTS: Global: C/U: €291.9;
P/U: 22.4; C/P: €13.0. Men present prescriptions more expensive
(+€1.5), but women are more expensive (€305.6 vs. €275.4)
because on average they demand 4.8 prescriptions more than
men P/U grows exponentially (R2 = 0.929) until 89 y.o.(63.4).
Min: 4.3(10 y.o.). C/P varies considerably until 28 y.o. (avg:
€10.0; Pearson v.c:32.1). Prescriptions of growth hormone
increase the C/P a 83% among 12–16 y.o. Since 29 y.o. C/P sta-
bilizes (avg: €12.9; Pearson v.c.:8.6) presenting an upward trend
at ages close to retirement age (chronic illnesses and copayment).
C/U behaves exponentially until 88 y.o. (R2 = 0.962). At 88 y.o.
C/U is 3 times higher than global average and 28.5 higher than
at 5 y.o. Since 17 y.o., women consume more medicines than
men, but men present prescriptions more expensive than women
so there are alternations in C/U. U/Pop at 70 y.o. is 1.84 times
higher than at 30 y.o.(prob.0.90 vs. 0.49), and the difference in
C/U is €569. For equal ages, there are also differences in U/Pop
between primary health care teams (PHCTs) because of, for
example, other socio-economic and geographical variables.
CONCLUSIONS: It’s important to include age and gender of
users in comparative analysis between PHCTs in order to con-
sider differences in the population pyramid and in utilization
levels. Benchmarking activity between PHCTs is being carried
out monthly with these three standardized indicators. These
reports allow to locate inefﬁciency with more accuracy and to
apply measures more effective.
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